Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
about
Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumabHepatic manifestations of non-steroidal inflammatory bowel disease therapyA systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease.Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysisMedical management of Crohn's disease.The impact of biologics on health-related quality of life in patients with inflammatory bowel disease.Managing refractory Crohn's disease: challenges and solutionsFrom historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's diseaseCombination therapy for the treatment of Crohn's disease.Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.Both Th1 and Th17 are immunopathogenic but differ in other key biological activities.An evidence-based review of natalizumab therapy in the management of Crohn's disease.Advances in surgical approaches to Crohn's disease: minimally invasive surgery and biologic therapy.Investigational agents for Crohn's disease.Anti-adhesion molecule therapy for inflammatory bowel diseaseRecent advances in cytokines: therapeutic implications for inflammatory bowel diseases.Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.An evidence-based systematic review on medical therapies for inflammatory bowel disease.Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis.Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.New biologic therapeutics for ulcerative colitis and Crohn's disease.The role of integrin antagonists in the treatment of inflammatory bowel disease.Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.Natalizumab in the treatment of Crohn's disease patients.Optimizing the use of biologic therapies in the treatment of inflammatory bowel disease.Elevated risk of opportunistic viral infection in patients with Crohn's disease during biological therapies: a meta analysis of randomized controlled trials.Natalizumab for the treatment of Crohn's disease.Immunotoxicity profile of natalizumab.Long-term Combination Therapy with Anti-TNF plus Vedolizumab Induces and Maintains Remission in Therapy-refractory Ulcerative Colitis.Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis.
P2860
Q26750456-6BBF2D51-96FC-4873-B972-AC3A1B666A3FQ26773684-07F0533D-E940-4326-BED7-FA2F4491E82FQ33514539-4CF738B4-A438-45F6-9827-0BD0847CBD13Q33564492-09F2BDCA-06E7-4F6F-A2B8-960E68F66388Q34046139-1B68105C-DC2E-4299-8380-AA56C59CD053Q35026298-252B2981-D56C-4928-BF55-504D5259F2FEQ35460367-5E7D3429-0F1C-48F5-8193-4E0F9F682C11Q35559305-D80D370C-8A59-4D5B-A7FE-E0207F06B695Q35714202-05450826-54A9-412C-86C9-A423B97BA706Q37346024-14CF82A3-6DE3-4918-AA02-57116836B1C4Q37365830-89F47C7F-BDAF-408B-9990-BB1BC16D4539Q37462968-E312F5B4-945A-4C8F-8CE2-56867E1FA893Q37754695-8F883ABB-7E4E-4E19-8737-654F6FED2210Q37788217-B29E0599-A7EC-46DA-881B-4B9254F536D0Q37823325-4FC272C6-A155-4A79-838B-49F72788764FQ37847059-05C20D7C-12EC-4F82-93C5-4DCE793D3E1FQ37853359-CBD0E96D-124E-4A46-A2D2-F521E93ABBEDQ37862584-B91A8714-FAD4-4E16-9F8D-D0E2BE7D0C05Q38053495-D28C7E5C-5355-42A4-BC77-00D29F547ED7Q38128946-82FE46BC-E60C-4716-B3E4-B52485FD14B8Q38130407-B321AB9D-F970-482D-B96B-83DFBB2C3D24Q38176154-8C68ED0A-F1C0-4C22-8200-1141D3AFCFF8Q38185687-467D8791-714D-4AC2-9036-1E28CD6D9585Q38257410-D893D0E5-5D29-49F2-97FC-2AE08332FC6CQ38412914-512575D5-8E1F-40E5-AA77-ABBDD9206406Q38436580-C2A71F3C-CC1B-4266-B061-E85E0966ED60Q38501680-E7979883-324A-4D53-9D57-071C3D671A16Q38542151-2E26704F-0191-492F-B9CD-379792EF6804Q38612843-205E965B-AC7B-4B1C-B0CD-E3B38F9D0581Q42043806-25C8E5C8-7477-46B9-B5F9-EF00797481E7Q42281646-B5031E5C-73F2-43B2-980D-CDA311683874Q44864916-238493FB-E66D-4AED-AA5A-A90D23F22CE4Q45979796-C03C21E4-EAB7-4DA7-9376-ED2D5CDD31EDQ49596989-1EEAF837-F735-4242-A7B0-564EBA09E02DQ51584924-0B6BCBC7-86D1-42D3-A889-837BDE21BF86Q55100632-F74447C7-A01B-4348-AFC1-176F85E9765E
P2860
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Safety and tolerability of con ...... on while receiving infliximab.
@ast
Safety and tolerability of con ...... on while receiving infliximab.
@en
Safety and tolerability of con ...... on while receiving infliximab.
@nl
type
label
Safety and tolerability of con ...... on while receiving infliximab.
@ast
Safety and tolerability of con ...... on while receiving infliximab.
@en
Safety and tolerability of con ...... on while receiving infliximab.
@nl
prefLabel
Safety and tolerability of con ...... on while receiving infliximab.
@ast
Safety and tolerability of con ...... on while receiving infliximab.
@en
Safety and tolerability of con ...... on while receiving infliximab.
@nl
P2093
P2860
P356
P1476
Safety and tolerability of con ...... ion while receiving infliximab
@en
P2093
Bruce E Sands
Charles F Barish
Deborah Hilton
Jack Spainhour
Lawrence Goldberg
Rena Harrigan
Richard Kozarek
Ronald Goldblum
Scott Becker
Stephen B Hanauer
P2860
P356
10.1002/IBD.20014
P50
P577
2007-01-01T00:00:00Z